@felixprehn this is where I separate investing research from “find the next 20x” content. $NVDA and $PLTR look obvious in hindsight. They were NOT obvious when the market was pricing execution risk, competition, capital requirements, and uncertainty. That is survivorship bias. $NNE is a good example of how I would approach an emerging company from a Business Analytics mindset. The thesis is interesting: Nuclear demand is rising. AI and data centers need reliable power. Microreactors could serve remote infrastructure, defense, industrial sites, and eventually commercial applications. And @nano_nuclear has made tangible regulatory progress with its KRONOS MMR program entering formal NRC review. But I am not asking: “Can this become the next NVIDIA?” I am asking: Can management execute? Can the technology clear NRC review? How much capital will commercialization require? What does dilution risk look like? Can fuel supply scale? What is the realistic deployment timeline? Who becomes the customer? What does unit economics look like after deployment? What competitive advantage survives once larger nuclear companies enter the market? That is how I research asymmetric opportunities. The upside story gets my attention. The balance sheet, regulatory pathway, competitive moat, and execution data determine whether it earns capital. Potential 20x return is NOT the thesis. Successful commercialization is the thesis. Sources: https://t.co/XzTkWcDQsc https://t.co/jYBLu1cubo EDUCATIONAL MARKET COMMENTARY ONLY!❗ NOT A RECOMMENDATION TO BUY, SELL, OR HOLD!❗ $NNE #NuclearEnergy #Investing #BusinessAnalytics #TheFinancialLedger #WealthCoachLathan